Jade Biosciences, Inc. Common Stock (JBIO) Stock Price

JBIOStock
$21.84+159.17%52W
Market Cap$1.39B
P/E
PEG Ratio
Div yield0.00%
Beta1.57

JBIO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)36.26%
Price vs S&P 500 (4W)5.22%
VGM Score58.16
Indicated Dividend Yield (Annual)0.00%

JBIO Earnings Surprise History

Q2 25-0.86est. -0.48
Q3 25-0.48est. -0.67
Q1 26-0.57est. -0.48
Q2 26-0.76est. -0.54

JBIO Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.44
4.44
4.41
4.41

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
JBIOJade Biosciences, Inc. Common Stock
C$21.84
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Jade Biosciences, Inc. Common Stock

Jade Biosciences develops immunotherapies targeting autoimmune diseases using antibody-based approaches. The company's lead candidate, JADE-001, targets the APRIL pathway for IgA nephropathy treatment and is advancing toward clinical-stage development. Jade maintains two additional antibody programs in preclinical development and was founded using technology licensed from Paragon Therapeutics.